Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Non-coding RNAs in Endocrinology

Ed. by Hardikar, Anandwardhan

1 Issue per year


Emerging Science

Open Access
Online
ISSN
2300-4258
See all formats and pricing
More options …

Identification of a novel miRNA targeting CD146 for suppression of angiogenesis

Sook Hyun Chung
  • Corresponding author
  • Macular Research Group, Clinical Ophthalmology and Eye Health, Save Sight Institute, The University of Sydney, Sydney, Australia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Weiyong Shen
  • Macular Research Group, Clinical Ophthalmology and Eye Health, the University of Sydney, Sydney, Australia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Mark Gillies
  • Macular Research Group, Clinical Ophthalmology and Eye Health, the University of Sydney, Sydney, Australia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-07-26 | DOI: https://doi.org/10.2478/micrnado-2014-0001

Abstract

Angiogenesis is the pathological process of forming new blood vessels from pre-existing vessels. It is one of the main features of many conditions such as cancer and inflammatory diseases. MicroRNAs (miRNAs) are small non-coding RNAs that regulate post-transcriptional gene expression. Recent studies have suggested that miRNAs play a significant role in angiogenesis. The study from Wang et al reported a novel angiomiR, miRNA-329, and its negative correlation with CD 146 expression in angiogenesis. These in vitro and in vivo studies introduce an appealing new way of treating angiogenesis by targeting CD146.

Keywords : Angiogenesis; MicroRNA; AngiomiR; miRNA--329

References

  • [1] De Falco, S., Antiangiogenesis therapy: an update after the first decade. Korean J Intern Med, 2014. 29(1): p. 1-11.CrossrefPubMedGoogle Scholar

  • [2] Crino, L. and G. Metro, Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur Respir Rev, 2014. 23(131): p. 79-91.Google Scholar

  • [3] Shord, S.S., et al., Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm, 2009. 66(11): p. 999-1013.Web of ScienceCrossrefPubMedGoogle Scholar

  • [4] Wang, S. and E.N. Olson, AngiomiRs--key regulators of angiogenesis. Curr Opin Genet Dev, 2009. 19(3): p. 205-11.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [5] Wang, S., et al., The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell, 2008. 15(2): p. 261-71.Google Scholar

  • [6] Kuehbacher, A., C. Urbich, and S. Dimmeler, Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci, 2008. 29(1): p. 12-5.CrossrefWeb of SciencePubMedGoogle Scholar

  • [7] Rupaimoole, R., et al., MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer, 2011. 30(6): p. 368-70.CrossrefGoogle Scholar

  • [8] Wang, P., et al., MicroRNA 329 suppresses angiogenesis by targeting CD146. Molecular and cellular biology, 2013. 33(18): p. 3689-99.Google Scholar

  • [9] Bu, P., et al., Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-kappaB activation. Molecular cancer therapeutics, 2006. 5(11): p. 2872-8.Google Scholar

  • [10] Kang, Y., et al., Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. Cell research, 2006. 16(3): p. 313-8. Google Scholar

About the article

Received: 2014-03-13

Accepted: 2014-04-29

Published Online: 2014-07-26

Published in Print: 2014-07-01


Citation Information: Non-coding RNAs in Endocrinology, Volume 1, Issue 1, ISSN (Online) 2300-4258, DOI: https://doi.org/10.2478/micrnado-2014-0001.

Export Citation

© 2014. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in